I didn't need to open the link to understand your point, but there's a difference between holding back some original, novel content....which makes perfect sense for the publication....and pre-publishing data that can't be interpreted by the consumers of a Company's press releases. It serves no useful purpose to compare apples and oranges, even if the author notes that they are comparing apples and oranges.
e.g. I can't make much use of the data reported here. The last sentence is the only distinction of value....all the numbers have little meaning as far as I can tell. They can't be used for comparison purposes, yet they are....that doesn't seem right to me. "To put the new RBL testing results in additional context, an article published in Nature showed that Gilead Sciences’ Remdesivir™ achieved 50 percent inhibition against SARS-CoV-2, in a time-of-addition experiment, at a concentration of 3.7 µM in Vero (animal) cells. Remdesivir™ has received attention worldwide as one of the few effective therapies for treating COVID-19, gaining varying levels of authorized use in the U.S., E.U., U.K., India, Singapore, Japan, and Australia.
In the RBL assay (which included Brilacidin pre-incubated with virus), Brilacidin exhibited approximately 90 percent inhibition against SARS-CoV-2 at a concentration similar to that of Remdesivir™, which again reported 50 percent inhibition of the coronavirus. The Brilacidin inhibition assay was tested in a human lung epithelial cell line, with Remdesivir™ tested in Vero cells. The RBL data also supports Brilacidin showing an ability to inhibit viral entry into cells, a highly desirable mechanism of action as it is the first step in the infection process enabling viruses to be targeted outside the cell, whereas Remdesivir™ impacts viral replication only after the host cell has been infected."
I don't question the data points provided above, only their usefulness. Obviously just because I can't put the numbers together doesn't mean that they can't be put together, but instead of someone showing how that can be done, they're explaining why it shouldn't be doable. Making me nuts and unnecessarily encouraging my skepticism :o)
NO numbers are better than useless numbers. Some companies have figured out a way to promote their drugs without resorting to comparisons with other drugs and non sequiturial (made that up just for you) numerical comparisons. What THEIR DRUG can do and has done is promotional enough, if they are meaningful things.
News 
Market Data 
Discover 
